Cooperative Agreement UG3CA290468
Award Date 8/15/25
Completion Date 5/31/27
Dollars Obligated $705K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Arizona, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $173,500.00 to Health Research, Inc. to investigate the effects of CXCR1/2 inhibition on the immune microenvironment of patients with multiple myeloma. The primary goal is to characterize the phenotype and transcriptional changes in myeloid cells in the tumor microenvironment of multiple myeloma patients, and to evaluate the efficacy of CXCR2 inhibitors in preclinical models. The...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $644,190 to the Mayo Clinic to conduct research on "Metabolic Strategies to Eradicate Premalignant Clonal Plasma Cells and Prevent the Development of Multiple Myeloma." The award period runs from September 1, 2024 to August 31, 2026. The grant supports the Mayo Clinic's expertise in cancer research, clinical trials, and translational medicine to...
- The National Cancer Institute awarded a $156,080 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Mayo Clinic Arizona, a subsidiary of Mayo Collaborative Services, Inc. The grant, with an award date of December 25, 2025 and an ultimate completion date of July 31, 2028, will fund research to elucidate the functional role of KLRG1-expressing conventional helper T cells (TCONV) in the tumor microenvironment and develop a novel immunotherapy to selectively deplete this...
- This federal Project Grant award of $620,521, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports an integrated mathematical modeling approach to define how the aging bone ecosystem drives multiple myeloma evolution and treatment response. The key products and services to be delivered under this 5-year award, which commenced on January 1, 2025, include: Developing a novel hybrid cellular automata mathematical model to describe the...
- This federal Cooperative Agreement award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $266,736.00 to the Mayo Clinic for a project focused on "Assay Validation of Cell-Free DNA Amplified DNA Junctions for High Grade Glioma Monitoring." The award period runs from August 1, 2025 to July 31, 2026. The project aims to develop and validate new diagnostic tools and technologies to improve early detection, monitoring, and management of...
- The National Cancer Institute awarded Emory University a $1,295,039 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to conduct research on improving immune modulation for smoldering myeloma, a precursor state to multiple myeloma. The project aims to evaluate how properties of immune cells in smoldering myeloma correlate with progression to clinical myeloma, examine changes in immune cells during therapy with Iberdomide or Iberdomide plus Dexamethasone, and...
- This $462,092 Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is focused on investigating novel immune checkpoint targets for the topical immunoprevention of keratinocytic skin cancer. The award is held by the University of Arizona and will run from August 1, 2025 to July 31, 2027. The key objectives of the project are to 1) use human samples to identify novel immune checkpoint proteins that are upregulated early in the skin...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Mayo Clinic Jacksonville (a nonprofit corporation registered as Scott Lynch MD) to develop a first-in-class non-muscle myosin II (NMII) inhibitor, MT-125, for the treatment of glioblastoma. The $607,634 award, effective January 1, 2025 through December 31, 2029, supports research to uncover the mechanisms behind the synergistic effects of MT-125 when combined with...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop novel T-cell imaging techniques to better understand therapy resistance and treatment efficacy of bispecific T-cell engager (BiTE) antibodies targeting B-cell maturation antigen (BCMA) and G protein coupled receptor class C group 5 member D (GPRC5D) in relapsed and refractory multiple myeloma patients. The...
- This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $3,291,419.00 to Mayo Clinic Arizona to conduct a Phase 1 clinical trial using autologous, MUC1-activated T cells expanded from peripheral blood in patients with relapsed and resistant ovarian cancer. The award period runs from September 1, 2024 to August 31, 2028. This research aims to advance innovative cellular immunotherapy approaches to transform...